Take the next step with EndoPredict®

Get started with EndoPredict by downloading the provider guide.

Take the next step with EndoPredict®

Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.

EndoPredict® Breast Cancer Prognostic Test

Genomic testing to help tailor breast cancer treatment decisions

For patients with ER+, HER2-, node negative or node positive breast cancer, EndoPredict provides three individualized results to use to help determine the right breast cancer treatment decisions.

EndoPredict® Breast Cancer Prognostic Test

Genomic testing to help tailor breast cancer treatment decisions

For patients with ER+, HER2-, node negative or node positive breast cancer, EndoPredict provides three individualized results to use to help determine the right breast cancer treatment decisions.

Confident decision-making for breast cancer treatment starts with risk identification

EndoPredict is a next generation prognostic genomic test that predicts individual risk of early and late breast cancer recurrence across years 0-15. By knowing your patient’s individualized absolute chemotherapy benefit and predicted distant recurrence up to 15 years at the time of diagnosis, the EndoPredict test helps you make informed adjuvant treatment decisions for your breast cancer patients.

EndoPredict helps you answer:

1

What is the chance my patient’s cancer will return within 10 years?

2

How will their cancer potentially respond to chemotherapy?

3

Can they safely stop hormone treatment (endocrine therapy) at five years?

EndoPredict’s proven prognostic power delivers results you can trust for critical treatment decisions

EndoPredict is validated in more than 4,000 breast cancer patients with ER+, HER2-, N0 and N1 disease. No other test provides the long-term results and robust benefits of EndoPredict.

Comprehensive results to guide decisions

The EndoPredict report provides a clear, individualized risk of recurrence for years 0-10 based on a tumor’s specific biology and pathology. Patients will also receive an individualized absolute chemotherapy benefit specific to their tumor. By knowing this information, you’ll know your patient’s risk of recurrence at 5-15 years and whether they might safely forego extended endocrine therapy.

Better identification of low-risk patients

EndoPredict better identifies a large percentage of low-risk patients (average of 6% recurrence).1,2,3

More than 70% NO Patients - graphic

More than 70% of N0 patients3,4

Up to 30% of N+ patients - graphic

Up to 30% of N+ patients3,4

EndoPredict Test Kit

The full EndoPredict report includes

  • 12-gene molecular score
  • Tumor stage
  • Nodal status
  • EPclin score
  • Recurrence score

How to test with EndoPredict

Provider completes the test request form (in the portal or via paper TRF)

Myriad’s laboratory processing staff contacts your pathology partner to directly obtain the tumor sample.

Results are sent to the ordering provider (in the portal or via mail)

What to expect with every EndoPredict test

Actionable

Every EndoPredict test provides actionable results to guide treatment decisions, including a specific score that indicates whether your patient’s cancer is at a low or high risk of returning within the next 10 years.

Affordable

Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.

Accurate

Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.

EndoPredict resources

References:

  1. Filipits M, Rudas M, Jakesz R, et al; for EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
  2. Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016;108(11):djw149. doi:10.1093/jnci/djw149.
  3. Data on file. Myriad Genetics Inc.
  4. Sestak I, Buus R, Cuzick J, et al; Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. Published online Feb 15, 2018 doi:10.1001/jamaoncol.2017.5524.